Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery

Journal of Pharmaceutical Sciences

Volumn 104, Issue 5, 2015, Pages 1677-1690

  Addo, Richard T ^a   Yeboah, Kwame G ^b   Siwale, Rodney C ^c   Siddig, Aladin ^d   Jones, Alphia ^e   Ubale, Ruhi V ^a,f   Akande, Janet ^g   Nettey, Henry ^h   Patel, Neil J ^a   Addo, Evelyn ^a   D'Souza, Martin J ^e  

^a UNION UNIVERSITY   (United States)

^b HARDING UNIVERSITY   (United States)

^c WESTERN NEW ENGLAND UNIVERSITY   (United States)

^d Robert C Byrd Center for Pharmacy Education   (United States)

^e MERCER UNIVERSITY   (United States)

^f LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^g Lonza Inc   (United States)

^h UNIVERSITY OF GHANA   (Ghana)

Author keywords

Albumin; Atropine; Chitosan; Microparticles; Micropheres; Mydriasis; Nanoparticles; Ocular delivery

Indexed keywords

ATROPINE; BOVINE SERUM ALBUMIN; CHITOSAN; MICROSPHERE;

ACCOMMODATION PARALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MORPHOLOGY; MYDRIASIS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POROSITY; SCANNING ELECTRON MICROSCOPE; SPRAY DRYING; SURFACE PROPERTY; ZETA POTENTIAL; ANIMAL; BOVINE; CELL CULTURE; CORNEA; DRUG EFFECTS; EYE; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; RABBIT; SYNTHESIS;

ANIMALS; ATROPINE; CATTLE; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CORNEA; DRUG DELIVERY SYSTEMS; EYE; HUMANS; MICROSPHERES; MYDRIASIS; RABBITS; SERUM ALBUMIN, BOVINE;

EID: 84926662454     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24380     Document Type: Article

References (77)

1. Mathiowitz E, Chickering D, Jacob JS, Santos C. 1999. Bioadhesive drug delivery systems. In Encyclopedia of controlled drug delivery; Mathiowitz E, Ed. Vol I. New York: Wiley, pp 9-44.
2. Vasir JK, Tambwekar K, Garg S. 2003. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 255:13-32.
3. Alonso MJ, Sanchez A. 2003. The potential of chitosan in ocular delivery. J Pharm Pharmacol 55:1451-1463.
4. Diebold Y, Calonge M. 2010. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596-609.
5. Chandy T, Sharma CP. 1990. Chitosan - As a biomaterial. Biomaterials Artif Cells Artif Organs 18(1):1-24.
6. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81-96.
7. George M, Abraham TE. 2006. Polyionic hydrocolloids for the intestinal delivery of protein drugs, alginate and chitosan - A review. J Control Release 114 (1):1-14.
8. Gan O, Wang T, Cochrane C, McCarron P. 2005. Modulation of surface charge particle size and morphological properties of chitosan - TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces 44(2-3):65-73.
9. Chandy T, Sharma CP. 1992. Chitosan beads and granules for oral sustained delivery of nifedipine: In vitro studies. Biomaterials 13(13):949-952.
10. Gupta KC, Ravi Kumar MNV. 2000. Drug release behavior of beads and microgranules of chitosan. Biomaterials 21(11):1115-1119.
11. Mi FL, Sung HW, Shyu SS. 2002. Drug release from chitosan-alginate complex beads reinforced by a naturally occurring crosslinking agent. Carbohydr Polym 48 (1):61-72.
12. Lubben MVD, Van Opdorp FAC, Hengeveld MR, Onderwater JJM, Koerten HK, Verhoef JC, Borchard G, Junginger HE. 2002. Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model. J Drug Target 10 (6):449-456.
13. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin D JA, Jiskoot W. 2007. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 25 (1):144-153.
14. Shah DN, Rectenwall-Work SM, Anseth KS. 2008. The effect of bioactive hydrogels on the secretion of extracellular matrix molecules by valvular intestinal cells. Biomaterials 19:2070-2072.
15. Amiji MM. 1995. Permeability and blood compatibility properties of chitosan-poly(ethylene oxide) blend membranes for haemodialysis. Biomaterials 16:593-599.
16. Kristmundsdottir T, Ingvardottir K, Saemundsdottir G. 1995. Chitosan matrix tablets: The influence of excipients on drug release. Drug Dev Ind Pharm 21:1591-1598.
17. Sabnis S, Rege P, Block LH. 1997. Use of chitosan in compressed tablets of diclofenac sodium: Inhibition of drug release in an acidic environment. Pharm Dev Technol 2:243-255.
18. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331.
19. Danielsen S, Varum KM, Stokke BT. 2004. Structural analysis of chitosan medicated DNA condensation by AFM: Influence of chitosan molecular parameters. Biomacromolecules 5(3):928-936.
20. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. 2004. Chitosan-DNA nanoparticles as nonviral vectors in gene therapy: Strategies to improve transfection efficacy. Eur J Pharm Biopharm 57(1):1-8.
21. Wong K, Sun G, Zhang X, Dai H, Liu Y, He C, Leong KW. 2006. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem 17 (1):152-158.
22. Iwasaki N, Yamane ST, Majima T, Kasahara Y, Minami A, Harada K, Nonaka S, Maekawa N, Tamura H, Tokura S, Shiono M, Monde K, Nishimura S. 2004. Feasibility of polysaccharide hybrid materials for scaffolds in cartilage tissue engineering: Evaluation of chondrocyte adhesion to polyion complex fibres prepared from alginate and chitosan. Biomacromolecules 5(3):828-833.
23. Zhu AP, Ming Z, Jian S. 2005. Blood compatibility of chitosan/heparin complex surface modified ePTFE vascular graft. Appl Surf Sci 241 (3-4):485-492.
24. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. 2007. Chitosan solution enhances both humoral and cell-medicated immune responses to subcutaneous vaccination. Vaccine 25 (11):2085-2094.
25. Ito M, Ban A, Ishihara M. 2000. Anti-ulcer effects of chitin and chitosan, healthy foods, in rats. Jpn J Pharmacol 82:218-225.
26. Berger J, Reist M, Mayer JM, Felt O, Gurny R. 2004. Structure and interactions in chitosan hydrogels formed by complexation or aggregations for biomedical applications. Eur J Pharm Biopharm 57 (1):35-52.
27. Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R. 2004. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 57 (1):19-34.
28. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. 1992. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 78:43-48.
29. Zimmer A, Mutschler E, Lambrecht G, Mayer D, Kreuter J. 1994. Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system. Pharm Res 11 (10):1435-1442.
30. He P, Davis SS, Illum L. 1998. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm 166 (1):75-88.
31. Bernkop-Schnurch A, Humenberger C, Valenta C. 1998. Basic studies on bioadhesive delivery systems for peptide and protein drugs. Int J Pharm 165 (2):217-225.
32. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. 1999. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55-65.
33. Robinson JR, Mlynek GM. 1995. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 16:45-50.
34. Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. 1999. Topical use of chitosan in ophthalmology: Tolerance assessment and evaluation of precorneal retention. Int J Pharm 180:185-193.
35. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. 2004. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 274:1-33.
36. Markey ML, Bowman LN, Bergamini MVM. 1989. Chitin and chitosan - Source, chemistry, biochemistry, physical properties and application. London, UK: Elsevier.
37. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GGM. 2003. Cell transfection in vitro and in vivo with nontoxic TATpeptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100:1972-1977.
38. De Campos AM, Diebold Y, Carvolho ELS, Sanchez A, Alonso MJ. 2004. Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21(5):803-810.
39. Rathore KS, Nema RK. 2009. Insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res 1 (1):1-5.
40. Harmia T, Speiser P, Kreuter J. 1986. A solid colloidal drug delivery system for the eye: Encapsulation of pilocarpine in nanoparticles. J Microencapsul 3:3-12.
41. Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. 1991. Improvement of ocular penetration of amikacin sulphate by association to poly-(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol 43:548-552.
42. Losa C, Marchal-Heussler L, Orallo F, Vila-Jato JL, Alonso MJ. 1993. Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol. Pharm Res 10:80-87.
43. Calvo P, Sanchez A, Martinez J, Lopez MI, Calonge M, Pastor JC, Alonso MJ. 1996. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 13:311-315.
44. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. 1996. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol 48:1147-1152.
45. Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G. 1997. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol 49:737-742.
46. Calvo P, Vila-Jato JL, Alonso MJ. 1996. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions as ocular drug carriers. J Pharma Sci 85:530-536.
47. Kramer PA. 1974. Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 63(10):1646-1647.
48. Yeboah KG, D'Souza MJ. 2009. Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul 26(2):166-179.
49. ThakkarH, Sharma RK, Mishra AK, Chuttani K, Murthy RR. 2005. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS Pharm Sci Tech 6:E65-E73.
50. Manny RE, Hussein M, Scheiman M, Kurtz D, Niemann K, Zinzer K, the Comet Study Group. 2001. Tropicamice (1%): An effective cycloplegic agent for myopic children. Invest Ophthalmol Vis Sci 42 (8):1728-1735.
51. Farhood QK. 2012. Cycloplegic refraction in children with cyclopentolate versus atropine. J Clin Exp Ophthalmol 3(7):1-6.
52. Chia A, Chua W-H,Wen L, Fong A, Goon YY, Tan D. 2014. Atropine for the treatment of childhood myopia: Changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 157(2):451-457.
53. Ahmad NN, Dimascio J, Knowlton RG, Tasman WS. 1995. Stickler syndrome. A mutation in the nonhelical 3′ end of type II procollagen gene. Arch Ophthalmol 113(11):1454-1457.
54. Krolicki TJ, Tasman W. 1995. Cataract extraction in adults with retinopathy of prematurity. Arch Ophthalmol 113(2):173-177.
55. Ngezahayo A, Lang F, Kolb HA. 1995. Cholecystokinin-octapeptide affects the fluorescence signal of a single pancreatic acinar cell loaded with the acrylodan-labelled MARCKS peptide, a protein kinase C substrate. Pflugers Arch 429(6):805-808.
56. Regillo CD, Brown GC, Savino PJ, Byrnes GA, Benson WE, Tasman WS, Sergott RC. 1995. Diabetic papillopathy. Patient characteristics and fundus findings. Arch Ophthalmol 113 (7):889-895.
57. nd ed. Edinburgh UK: Churchill Livingstone, section A, pp 40-44.
58. Morton RA, Creed RH. 1939. The conversion of carotene to vitamin A(2) by some fresh-water fishes. Biochem J 33(3):318-324.
59. Hoefnagel D. 1961. Toxic effects of atropine and homatropine eye drops in children. N Engl J Med 264:168-171.
60. Akande J, Yeboah KG, Addo RT, Siddig A, Oettinger CW, D'Souza MJ. 2010. Targeted delivery of antigens to the gut-associated lymphoid tissues: 2. Ex vivo evaluation of lectin-labeled albumin microspheres for targeted delivery of antigens to the M-cells of the Peyer's patches. J Microencapsul 27 (4):325-336.
61. Yeboah KG, Akande J, Addo RT, Siwale RC, Aninkorah-Yeboah K, Siddig A. 2014. In vitro and ex vivo characterization of lectin-labeled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery. J Drug Target 22(1):34-47.
62. Shastri PN, Ubale RV, D'Souza MJ. 2013. Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles. Drug Dev Ind Pharm 39:164-175.
63. Ubale RV, D'Souza MJ, Infield DT, McCarty NA, Zughaier SM. 2013. Formulation of meningococcal capsular polysaccharide vaccineloaded microparticles with robust innate immune recognition. J Microencapsul 30:28-41.
64. Patel N, Addo RT, Ubale R, Uddin MN, D'Souza M, Jobe L. 2014. The effect of antisense to NF-κB in an albumin microsphere formulation on the progression of left-ventricular remodeling associated with chronic volume overload in rats. J Drug Target 22:796-804.
65. Ubale RV, Gala RP, Zughaier SM, D'Souza MJ. 2014. Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles. AAPS J 16:986-993.
66. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Pugilis G. 2002. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 15:3247-3255.
67. Addo RT, Siddig A, Siwale R, Patel NJ, Akande J, Uddin AN, D'Souza MJ. 2010. Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery. J Microencapsul 27:95-104.
68. Huguchi T. 1961. Rate of release of medicaments from ointment vases containing drugs in suspension. J Pharm Sci 50:874-875.
69. Guinedi AS, Mortada ND, Mansour S, Hathout RM. 2005. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71-82.
70. Tiyaboonchai W. 2003. Chitosan nanoparticles: A promising system for drug delivery. Naresuan Univ J 11(3):51-66.
71. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. 2009. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 136:2-13.
72. Benita S, Levy MY. 1993. Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemcial characteristics. J Pharm Sci 82:1069-1079.
73. Cai Y, Chen Y, Hong X, Lui Z, Yuan W. 2013. Porous microsphere and its applications. Int J Nanomed 8:1111-1120.
74. Gander B, Johansen P, Nam-Tran H, Merkle HP. 1996. Thermodynamic approach to protein microencapsulation into poly(D, L-lactide) by spray drying. Int J Pharm 129:51-61.
75. Tamber H, Johansen P, Merkle HP, Gander B. 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-376.
76. Miyazaki S, Ishii K, Nadai T. 1981. The use of chitin and chitosan as drug carriers. Chem Pharm Bull 29(10):3067-3069.
77. Prego C, Garcia M, Torres D, Alonso MJ. 2005. Transmucosal macromolecular drug delivery. J Control Release 101:151-162.